Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kolon Bounces Back From Failed Japan Invossa Deal With Bigger Mundipharma Alliance

Executive Summary

Kolon Life Science has reached a sizable license deal with Mundipharma for the development in Japan of the South Korean company’s first-in-class cell and gene therapy for osteoarthritis of the knee, easing uncertainties after an agreement with Mitsubishi Tanabe for the product collapsed last year.

Advertisement

Related Content

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
Disease Modifying Status Targeted As Kolon's Novel OA Therapy Enters US Phase III
Mitsubishi Seeks To Revoke Kolon Gene Therapy Deal But Damage Limited?
Kolon/Mitsubishi Gene Therapy Pact Paves Way For More Global Deals?
How Are Japan’s Regenerative Meds Regs Playing Out?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel